p16ink4a expression decreases during imiquimod treatment of anal intraepithelial neoplasia in human immunodeficiency virus-infected men and correlates with the decline of lesional high-risk human papillomavirus DNA load

被引:24
作者
Kreuter, A.
Wieland, U.
Gambichler, T.
Altmeyer, P.
Pfister, H.
Tenner-Racz, K.
Racz, P.
Potthoff, A.
Brockmeyer, N. H.
机构
[1] Ruhr Univ Bochum, Dept Dermatol & Allergol, D-44791 Bochum, Germany
[2] Univ Cologne, Inst Virol, Cologne, Germany
[3] Bernhard Nocht Inst Trop Dis, Hamburg, Germany
关键词
anal intraepithelial neoplasia; human immunodeficiency virus infection; human papillomavirus DNA load; human papillomavirus infection; p16(ink4a); proliferative biomarkers;
D O I
10.1111/j.1365-2133.2007.08004.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Human papillomavirus ( HPV)- associated anogenital cancers and their precursor lesions occur in excess in human immunodeficiency virus ( HIV)- infected patients despite the initiation of highly active antiretroviral therapy. In this context, a drastically increased relative risk for anal intraepithelial neoplasia ( AIN) exists in HIV- infected men having sex with men ( MSM). In a pilot study, imiquimod, a topical immune response modifier, has been reported to be beneficial in the treatment of AIN. Objectives To investigate the role of several biomarkers as potential adjuncts in the course of imiquimod treatment for AIN, and to determine whether these markers correlate with the course of high- risk HPV DNA load during imiquimod therapy. Methods Immunohistochemical staining was performed for p16ink4a, minichromosome maintenance protein ( MCM), Ki67, proliferating cell nuclear antigen ( PCNA) and p21(waf1) expression before and after 16 weeks of imiquimod treatment for AIN. High- risk HPV DNA load determinations were performed by realtime polymerase chain reaction with type- specific primers and probes for HPV types 16, 18, 31 and 33. Results Histopathological and virological analyses were performed in 21 HIVinfected MSM with histologically confirmed AIN. Eighteen ( 86%) patients had a complete histological clearance of AIN after imiquimod therapy. As previously shown, lesional high- risk HPV DNA load significantly decreased during imiquimod therapy. Moreover, a significant decline of p16(ink4a), Ki67, MCM and PCNA expression after treatment was observed, while p21waf1 expression changed nonsignificantly after imiquimod therapy. A significant correlation between the course of high- risk HPV DNA load and p16(ink4a) expression was observed during imiquimod treatment of AIN, whereas the decline of high- risk HPV DNA load did not significantly correlate with MCM, Ki67, PCNA or p21waf1 expression. Conclusions The significant decrease in p16 (ink4a) expression in correlation with the drop of lesional high- risk HPV load suggests that p16(ink4a) may be a useful adjunct for the evaluation of treatment response in HPV- associated malignancies and their precursor lesions.
引用
收藏
页码:523 / 530
页数:8
相关论文
共 30 条
[1]   p16INK4a expression correlates with degree of cervical neoplasia:: A comparison detection of high-risk with Ki-67 expression and HPV types [J].
Agoff, SN ;
Lin, P ;
Morihara, J ;
Mao, C ;
Kiviat, NB ;
Koutsky, LA .
MODERN PATHOLOGY, 2003, 16 (07) :665-673
[2]   Imiquimod for the treatment of skin cancer [J].
Burns, CA ;
Brown, MD .
DERMATOLOGIC CLINICS, 2005, 23 (01) :151-+
[3]   Surgical treatment of high-grade anal squamous intraepithelial lesions - A prospective study [J].
Chang, GJ ;
Berry, JM ;
Jay, N ;
Palefsky, JM ;
Welton, ML .
DISEASES OF THE COLON & RECTUM, 2002, 45 (04) :453-458
[4]   Screening HIV-infected individuals for anal cancer precursor lesions: A systematic review [J].
Chiao, Elizabeth Y. ;
Giordano, Thomas P. ;
Palefsky, Joel M. ;
Tyring, Stephen ;
El Serag, Hashem .
CLINICAL INFECTIOUS DISEASES, 2006, 43 (02) :223-233
[5]   New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections [J].
Doeberitz, MV .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (17) :2229-2242
[6]  
FENGER C, 1981, ACTA PATH MICRO IM A, V89, P463
[7]  
Freeman A, 1999, CLIN CANCER RES, V5, P2121
[8]   Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome [J].
Frisch, M ;
Biggar, IJ ;
Goedert, JJ .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (18) :1500-1510
[9]  
Gartel AL, 2002, MOL CANCER THER, V1, P639
[10]  
Indinnimeo M, 2000, J EXP CLIN CANC RES, V19, P471